Protocol Ledger

NCT06897644 · Phase III · RECRUITING

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Interventional Phase III clinical trial protocol NCT06897644 sponsored by Gruppo Oncologico del Nord-Ovest in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-27 Enrollment: 340 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06897644
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)340 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06897644
Protocol FieldVerified Registry Value
NCT IdentifierNCT06897644
Consolidated Lead SponsorGruppo Oncologico del Nord-Ovest
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment340 participants (ESTIMATED)
Registered Start Date2025-03-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06897644
Hospital Research SiteLocationSite Profile
Fondazione IRCCS CA' Granda Ospedale Maggiore PoliclinicoMilan, ItalyOpen Hospital Dossier ->
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI